Breast Cancer

Kathy S. Albain, MD, director, Breast Clinical Research Program, co-director, Breast Oncology Center, professor of medicine, Stritch School of Medicine, Loyola University Chicago, discusses a race-based study within the TAILORx trial.

Matthew P. Goetz, MD, discusses the impact of CDK4/6 inhibitors and their future role in the treatment of hormone receptor–positive breast cancer.

Recently, CDK 4/6 inhibitors have been changing practice in advanced HR-positive breast cancer, with 3 agents now having FDA-approved indications for use with endocrine therapy in the first-line setting.

Endocrine therapy, commonly used for lengthy periods in the adjuvant treatment of patients with breast cancer, does not have a detrimental effect on cognitive function in survivors of early-stage disease.

Kimberly S. Corbin, MD, radiation oncologist at the Mayo Clinic, discusses patient selection for proton therapy in breast cancer.

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses emerging therapies for the treatment of patients with triple-negative breast cancer (TNBC).

Melissa K. Accordino, MD, MS, discusses ways to improve the monitoring of patients with metastatic breast cancer.

Leon Ferre, MD, discusses new insights into the biology of triple-negative breast cancer that may lead to the emergence of novel therapies for these patients.

After years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.

Kimberly S. Corbin, MD, sheds light on the use of proton radiation therapy in the breast cancer space and which patients may benefit from this approach.